Subscribe To
Cassava sciences: my bullish take on biomarkers and ctad data
Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its app...
October 30, 2023, 3:30 am
Cognition therapeutics and collaborators at yale and actc announce oral late-breaking presentation on the start study in early alzheimer’s disease at ctad
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the...
October 27, 2023, 11:30 am
Biovie says blinded data points to hopeful alzheimer's treatment potential
BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its ...
October 25, 2023, 2:19 pm
Biogen to present new data at the clinical trials on alzheimer's disease (ctad) 2023 meeting
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc...
October 19, 2023, 7:30 am
General electric (ge) arm to invest $50m in new york facility
General Electric's (GE) arm, GE Vernova, is set to invest $50 million in the Schenectady, NY, facility to develop a new manufacturing assembly line fo...
May 24, 2023, 1:58 pm
Ac immune to present progress of alzheimer's disease programs targeting abeta and tau at the 15th ctad conference
Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine ...
November 23, 2022, 7:30 am
Athira pharma to present additional biomarker data from act-ad phase 2 study of fosgonimeton at the 2022 clinical trials on alzheimer's disease (ctad) conference
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurod...
November 21, 2022, 7:00 am
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm